期刊文献+

Differential diagnosis of benign and malignant branch duct intraductal papillary mucinous neoplasm using contrastenhanced endoscopic ultrasonography 被引量:12

Differential diagnosis of benign and malignant branch duct intraductal papillary mucinous neoplasm using contrastenhanced endoscopic ultrasonography
下载PDF
导出
摘要 AIM: To elucidate the role of contrast-enhanced endoscopic ultrasonography(CE-EUS) in the diagnosis of branch duct intraductal papillary mucinous neoplasm(BD-IPMN).METHODS: A total of 50 patients diagnosed with BDIPMN by computed tomography(CT) and endoscopic ultrasonography(EUS) at our institute were included in this study. CE-EUS was performed when mural lesions were detected by EUS. The diagnostic accuracy for identifying mural nodules(MNs) was evaluated by CT, EUS, and EUS combined with CE-EUS. In the patients who underwent resection, the accuracy of measuring MN height with each imaging modality was compared. The cut-off values to diagnose malignant BD-IPMNs based on MN height for each imaging modality were determined using receiver operating characteristic curve analysis.RESULTS: Fifteen patients were diagnosed with BD-IPMN with MNs and underwent resection. The remaining 35 patients were diagnosed with BD-IPMN without MNs and underwent follow-up monitoring. The pathological findings revealed 14 cases with MNs and one case without. The accuracy for diagnosing MNs was 92% using CT and 72% using EUS; the diagnostic accuracy increased to 98% when EUS and CE-EUS were combined. The accuracy for measuring MN height significantly improved when using CE-EUS compared with using CT or EUS(median measurement error value, CT: 3.3 mm vs CE-EUS: 0.6 mm, P < 0.05; EUS: 2.1 mm vs CE-EUS: 0.6 mm, P < 0.01). A cut-off value of 8.8 mm for MN height as measured by CE-EUS improved the accuracy of diagnosing malignant BDIPMN to 93%. CONCLUSION: Using CE-EUS to measure MN height provides a highly accurate method for differentiating benign from malignant BD-IPMN. AIM: To elucidate the role of contrast-enhanced endoscopic ultrasonography(CE-EUS) in the diagnosis of branch duct intraductal papillary mucinous neoplasm(BD-IPMN).METHODS: A total of 50 patients diagnosed with BDIPMN by computed tomography(CT) and endoscopic ultrasonography(EUS) at our institute were included in this study. CE-EUS was performed when mural lesions were detected by EUS. The diagnostic accuracy for identifying mural nodules(MNs) was evaluated by CT, EUS, and EUS combined with CE-EUS. In the patients who underwent resection, the accuracy of measuring MN height with each imaging modality was compared. The cut-off values to diagnose malignant BD-IPMNs based on MN height for each imaging modality were determined using receiver operating characteristic curve analysis.RESULTS: Fifteen patients were diagnosed with BD-IPMN with MNs and underwent resection. The remaining 35 patients were diagnosed with BD-IPMN without MNs and underwent follow-up monitoring. The pathological findings revealed 14 cases with MNs and one case without. The accuracy for diagnosing MNs was 92% using CT and 72% using EUS; the diagnostic accuracy increased to 98% when EUS and CE-EUS were combined. The accuracy for measuring MN height significantly improved when using CE-EUS compared with using CT or EUS(median measurement error value, CT: 3.3 mm vs CE-EUS: 0.6 mm, P < 0.05; EUS: 2.1 mm vs CE-EUS: 0.6 mm, P < 0.01). A cut-off value of 8.8 mm for MN height as measured by CE-EUS improved the accuracy of diagnosing malignant BDIPMN to 93%. CONCLUSION: Using CE-EUS to measure MN height provides a highly accurate method for differentiating benign from malignant BD-IPMN.
出处 《World Journal of Gastroenterology》 SCIE CAS 2015年第20期6252-6260,共9页 世界胃肠病学杂志(英文版)
关键词 Contrast-enhanced ENDOSCOPIC ULTRASONOGRAPHY ENDOSCOPIC ULTRASONOGRAPHY COMPUTEDTOMOGRAPHY Branch DUCT INTRADUCTAL papillary mucinousneoplasm MURAL nodules Contrast-enhanced endoscopic ultrasonography Endoscopic ultrasonography Computed tomography Branch duct intraductal papillary mucinous neoplasm Mural nodules
  • 相关文献

参考文献37

  • 1Adsay NV, Fukushima N, Furukawa T, Hruban RH, Klimstra DH,Kl-ppel G, Offerhaus GJA, Pitman MB, Shimizu M, Zamboni G.Intraductal neoplasms of the pancreas. In: Bosman FT, CarneiroF, Hruban RH, Theise ND. WHO classification of tumors of thedigestive system. Lyon: IARC Press, 2010: 304-313.
  • 2Kobari M, Egawa S, Shibuya K, Shimamura H, SunamuraM, Takeda K, Matsuno S, Furukawa T. Intraductal papillarymucinous tumors of the pancreas comprise 2 clinical subtypes:differences in clinical characteristics and surgical management.Arch Surg 1999; 134: 1131-1136 [PMID: 10522860 DOI: 10.1001/archsurg.134.10.1131].
  • 3Terris B, Ponsot P, Paye F, Hammel P, Sauvanet A, Molas G,Bernades P, Belghiti J, Ruszniewski P, Fléjou JF. Intraductalpapillary mucinous tumors of the pancreas confined to secondaryducts show less aggressive pathologic features as compared withthose involving the main pancreatic duct. Am J Surg Pathol 2000;24: 1372-1377 [PMID: 11023098 DOI: 10.1097/00000478-200010000-00006].
  • 4Matsumoto T, Aramaki M, Yada K, Hirano S, Himeno Y, ShibataK, Kawano K, Kitano S. Optimal management of the branch ducttype intraductal papillary mucinous neoplasms of the pancreas.J Clin Gastroenterol 2003; 36: 261-265 [PMID: 12590239 DOI:10.1097/00004836-200303000-00014].
  • 5Lévy P, Jouannaud V, O'Toole D, Couvelard A, Vullierme MP,Palazzo L, Aubert A, Ponsot P, Sauvanet A, Maire F, Hentic O,Hammel P, Ruszniewski P. Natural history of intraductal papillarymucinous tumors of the pancreas: actuarial risk of malignancy.Clin Gastroenterol Hepatol 2006; 4: 460-468 [PMID: 16616351DOI: 10.1016/j.cgh.2006.01.018].
  • 6Kang MJ, Jang JY, Kim SJ, Lee KB, Ryu JK, Kim YT, YoonYB, Kim SW. Cyst growth rate predicts malignancy in patientswith branch duct intraductal papillary mucinous neoplasms. ClinGastroenterol Hepatol 2011; 9: 87-93 [PMID: 20851216 DOI:10.1016/j.cgh.2010.09.008].
  • 7Tanaka M, Chari S, Adsay V, Fernandez-del Castillo C, FalconiM, Shimizu M, Yamaguchi K, Yamao K, Matsuno S. Internationalconsensus guidelines for management of intraductal papillarymucinous neoplasms and mucinous cystic neoplasms of thepancreas. Pancreatology 2006; 6: 17-32 [PMID: 16327281 DOI:10.1159/000090023].
  • 8Tanaka M, Fernández-del Castillo C, Adsay V, Chari S, Falconi M,Jang JY, Kimura W, Levy P, Pitman MB, Schmidt CM, ShimizuM, Wolfgang CL, Yamaguchi K, Yamao K. International consensusguidelines 2012 for the management of IPMN and MCN of thepancreas. Pancreatology 2012; 12: 183-197 [PMID: 22687371DOI: 10.1016/j.pan.2012.04.004].
  • 9Kubo H, Chijiiwa Y, Akahoshi K, Hamada S, Harada N, Sumii T,Takashima M, Nawata H. Intraductal papillary-mucinous tumors ofthe pancreas: differential diagnosis between benign and malignanttumors by endoscopic ultrasonography. Am J Gastroenterol 2001;96: 1429-1434 [PMID: 11374678].
  • 10Kobayashi G, Fujita N, Noda Y, Ito K, Horaguchi J, TakasawaO, Akaishi S, Tsuchiya T, Kobari M. Mode of progression ofintraductal papillary-mucinous tumor of the pancreas: analysisof patients with follow-up by EUS. J Gastroenterol 2005; 40:744-751 [PMID: 16082592 DOI: 10.1007/s00535-005-1619-7].

同被引文献70

引证文献12

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部